Does the media refer more to VKTX or KURA?

In the previous week, Kura Oncology had 5 more articles in the media than Viking Therapeutics. MarketBeat recorded 12 mentions for Kura Oncology and 7 mentions for Viking Therapeutics. Kura Oncology's average media sentiment score of 0.55 beat Viking Therapeutics' score of 0.37 indicating that Kura Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Kura Oncology 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KURA or PBLS?

In the previous week, Kura Oncology had 9 more articles in the media than Parabilis Medicines. MarketBeat recorded 12 mentions for Kura Oncology and 3 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.98 beat Kura Oncology's score of 0.55 indicating that Parabilis Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Parabilis Medicines 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, VCYT or KURA?

Veracyte has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veracyte $517.15M 6.70 $66.35M $1.41 30.57 Kura Oncology $67.48M 12.96 -$278.67M -$3.37 N/A

Is VCYT or KURA more profitable?

Veracyte has a net margin of 20.37% compared to Kura Oncology's net margin of -384.30%. Veracyte's return on equity of 9.26% beat Kura Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Veracyte 20.37% 9.26% 8.61% Kura Oncology -384.30% -207.18% -45.17%

Does the media prefer VCYT or KURA?

In the previous week, Kura Oncology had 6 more articles in the media than Veracyte. MarketBeat recorded 12 mentions for Kura Oncology and 6 mentions for Veracyte. Kura Oncology's average media sentiment score of 0.55 beat Veracyte's score of 0.54 indicating that Kura Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kura Oncology 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor XENE or KURA?

In the previous week, Kura Oncology had 4 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 12 mentions for Kura Oncology and 8 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.61 beat Kura Oncology's score of 0.55 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Kura Oncology 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KURA or LEGN?

In the previous week, Kura Oncology had 3 more articles in the media than Legend Biotech. MarketBeat recorded 12 mentions for Kura Oncology and 9 mentions for Legend Biotech. Kura Oncology's average media sentiment score of 0.55 beat Legend Biotech's score of -0.02 indicating that Kura Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Kura Oncology (KURA) Competitors

$9.83 -0.57 (-5.48%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$9.95 +0.12 (+1.22%)

As of 07:50 AM Eastern

Compare

KURA vs. VKTX, PBLS, VCYT, XENE, and LEGN

Should you buy Kura Oncology stock or one of its competitors? Kura Oncology's main competitors and comparable companies include Viking Therapeutics (VKTX), Parabilis Medicines (PBLS), Veracyte (VCYT), Xenon Pharmaceuticals (XENE), and Legend Biotech (LEGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kura Oncology compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Kura Oncology (NASDAQ:KURA) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

Viking Therapeutics currently has a consensus price target of $99.44, indicating a potential upside of 273.15%. Kura Oncology has a consensus price target of $25.69, indicating a potential upside of 161.32%. Given Viking Therapeutics' higher probable upside, equities research analysts clearly believe Viking Therapeutics is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Viking Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market.

In the previous week, Kura Oncology had 5 more articles in the media than Viking Therapeutics. MarketBeat recorded 12 mentions for Kura Oncology and 7 mentions for Viking Therapeutics. Kura Oncology's average media sentiment score of 0.55 beat Viking Therapeutics' score of 0.37 indicating that Kura Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kura Oncology	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

76.0% of Viking Therapeutics shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Kura Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Viking Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. Viking Therapeutics' return on equity of -94.56% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-94.56%	-82.75%
Kura Oncology	-384.30%	-207.18%	-45.17%

Kura Oncology has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
Kura Oncology	$67.48M	12.96	-$278.67M	-$3.37	N/A

Summary

Kura Oncology beats Viking Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Kura Oncology compare to Parabilis Medicines?

Kura Oncology (NASDAQ:KURA) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

Kura Oncology currently has a consensus target price of $25.69, indicating a potential upside of 161.32%. Parabilis Medicines has a consensus target price of $41.67, indicating a potential upside of 55.18%. Given Kura Oncology's stronger consensus rating and higher possible upside, research analysts plainly believe Kura Oncology is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Parabilis Medicines has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. Parabilis Medicines' return on equity of 0.00% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-384.30%	-207.18%	-45.17%
Parabilis Medicines	N/A	N/A	N/A

In the previous week, Kura Oncology had 9 more articles in the media than Parabilis Medicines. MarketBeat recorded 12 mentions for Kura Oncology and 3 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.98 beat Kura Oncology's score of 0.55 indicating that Parabilis Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Parabilis Medicines	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Parabilis Medicines has lower revenue, but higher earnings than Kura Oncology. Parabilis Medicines is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	12.96	-$278.67M	-$3.37	N/A
Parabilis Medicines	N/A	N/A	-$145.89M	-$2.13	N/A

Summary

Parabilis Medicines beats Kura Oncology on 7 of the 12 factors compared between the two stocks.

How does Kura Oncology compare to Veracyte?

Veracyte (NASDAQ:VCYT) and Kura Oncology (NASDAQ:KURA) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

Veracyte has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market.

Veracyte has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	6.70	$66.35M	$1.41	30.57
Kura Oncology	$67.48M	12.96	-$278.67M	-$3.37	N/A

Veracyte has a net margin of 20.37% compared to Kura Oncology's net margin of -384.30%. Veracyte's return on equity of 9.26% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	20.37%	9.26%	8.61%
Kura Oncology	-384.30%	-207.18%	-45.17%

In the previous week, Kura Oncology had 6 more articles in the media than Veracyte. MarketBeat recorded 12 mentions for Kura Oncology and 6 mentions for Veracyte. Kura Oncology's average media sentiment score of 0.55 beat Veracyte's score of 0.54 indicating that Kura Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kura Oncology	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Veracyte currently has a consensus price target of $55.78, suggesting a potential upside of 29.38%. Kura Oncology has a consensus price target of $25.69, suggesting a potential upside of 161.32%. Given Kura Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Kura Oncology is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Summary

Veracyte beats Kura Oncology on 8 of the 14 factors compared between the two stocks.

How does Kura Oncology compare to Xenon Pharmaceuticals?

Xenon Pharmaceuticals (NASDAQ:XENE) and Kura Oncology (NASDAQ:KURA) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Xenon Pharmaceuticals has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. Xenon Pharmaceuticals' return on equity of -43.98% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%
Kura Oncology	-384.30%	-207.18%	-45.17%

In the previous week, Kura Oncology had 4 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 12 mentions for Kura Oncology and 8 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.61 beat Kura Oncology's score of 0.55 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Kura Oncology	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 2.9% of Xenon Pharmaceuticals shares are owned by insiders. Comparatively, 7.6% of Kura Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Kura Oncology has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	443.65	-$345.91M	-$4.74	N/A
Kura Oncology	$67.48M	12.96	-$278.67M	-$3.37	N/A

Xenon Pharmaceuticals has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

Xenon Pharmaceuticals presently has a consensus target price of $70.14, suggesting a potential upside of 103.79%. Kura Oncology has a consensus target price of $25.69, suggesting a potential upside of 161.32%. Given Kura Oncology's higher probable upside, analysts clearly believe Kura Oncology is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Summary

Xenon Pharmaceuticals beats Kura Oncology on 10 of the 16 factors compared between the two stocks.

How does Kura Oncology compare to Legend Biotech?

Kura Oncology (NASDAQ:KURA) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

Kura Oncology has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	12.96	-$278.67M	-$3.37	N/A
Legend Biotech	$1.03B	3.37	-$296.80M	-$0.25	N/A

In the previous week, Kura Oncology had 3 more articles in the media than Legend Biotech. MarketBeat recorded 12 mentions for Kura Oncology and 9 mentions for Legend Biotech. Kura Oncology's average media sentiment score of 0.55 beat Legend Biotech's score of -0.02 indicating that Kura Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kura Oncology has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

Kura Oncology presently has a consensus price target of $25.69, suggesting a potential upside of 161.32%. Legend Biotech has a consensus price target of $55.07, suggesting a potential upside of 208.01%. Given Legend Biotech's higher possible upside, analysts clearly believe Legend Biotech is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Legend Biotech	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53

70.9% of Legend Biotech shares are held by institutional investors. 7.6% of Kura Oncology shares are held by insiders. Comparatively, 0.0% of Legend Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Legend Biotech has a net margin of -7.21% compared to Kura Oncology's net margin of -384.30%. Legend Biotech's return on equity of -8.71% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-384.30%	-207.18%	-45.17%
Legend Biotech	-7.21%	-8.71%	-5.40%

Summary

Legend Biotech beats Kura Oncology on 8 of the 15 factors compared between the two stocks.

Get Kura Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KURA vs. The Competition

Export

Metric	Kura Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$924.75M	$3.93B	$7.27B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	N/A	10.78	202.90	19.69
Price / Sales	12.96	1,146.43	561.48	81.34
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	4.92	16.70	10.61	6.03
Net Income	-$278.67M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-7.87%	-4.43%	-2.89%	-2.34%
1 Month Performance	-14.97%	-12.49%	-7.37%	-5.31%
1 Year Performance	2.18%	7.63%	3.00%	-2.94%

Kura Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KURA Kura Oncology	3.5954 of 5 stars	$9.83 -5.5%	$25.35 +157.9%	-1.0%	$924.75M	$67.48M	N/A	260	Analyst Forecast
VKTX Viking Therapeutics	3.3142 of 5 stars	$29.28 -2.2%	$99.67 +240.4%	-21.4%	$3.77B	N/A	N/A	65
PBLS Parabilis Medicines	2.1981 of 5 stars	$29.53 -2.5%	$41.67 +41.1%	N/A	$3.74B	N/A	N/A	145
VCYT Veracyte	4.2631 of 5 stars	$47.67 +4.1%	$55.78 +17.0%	+26.5%	$3.68B	$561.90M	33.81	755
XENE Xenon Pharmaceuticals	4.4056 of 5 stars	$37.57 -1.2%	$69.13 +84.0%	-13.9%	$3.68B	N/A	N/A	364	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KURA) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kura Oncology (KURA) Competitors

KURA vs. VKTX, PBLS, VCYT, XENE, and LEGN

How does Kura Oncology compare to Viking Therapeutics?

Summary

How does Kura Oncology compare to Parabilis Medicines?

Summary

How does Kura Oncology compare to Veracyte?

Summary

How does Kura Oncology compare to Xenon Pharmaceuticals?

Summary

How does Kura Oncology compare to Legend Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KURA vs. The Competition

Kura Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kura Oncology (KURA) Competitors

KURA vs. VKTX, PBLS, VCYT, XENE, and LEGN

How does Kura Oncology compare to Viking Therapeutics?

Do analysts rate VKTX or KURA?

Which has more volatility & risk, VKTX or KURA?

Does the media refer more to VKTX or KURA?

Do institutionals & insiders have more ownership in VKTX or KURA?

Is VKTX or KURA more profitable?

Which has higher earnings and valuation, VKTX or KURA?

Summary

How does Kura Oncology compare to Parabilis Medicines?

Do analysts rate KURA or PBLS?

Is KURA or PBLS more profitable?

Does the media prefer KURA or PBLS?

Which has preferable valuation and earnings, KURA or PBLS?

Summary

How does Kura Oncology compare to Veracyte?

Which has more risk and volatility, VCYT or KURA?

Which has higher valuation & earnings, VCYT or KURA?

Is VCYT or KURA more profitable?

Does the media prefer VCYT or KURA?

Do analysts rate VCYT or KURA?

Summary

How does Kura Oncology compare to Xenon Pharmaceuticals?

Is XENE or KURA more profitable?

Does the media favor XENE or KURA?

Do institutionals & insiders hold more shares of XENE or KURA?

Which has preferable earnings and valuation, XENE or KURA?

Which has more volatility & risk, XENE or KURA?

Do analysts recommend XENE or KURA?

Summary

How does Kura Oncology compare to Legend Biotech?

Which has stronger earnings and valuation, KURA or LEGN?

Does the media prefer KURA or LEGN?

Which has more volatility & risk, KURA or LEGN?

Do analysts recommend KURA or LEGN?

Do institutionals & insiders believe in KURA or LEGN?

Is KURA or LEGN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KURA vs. The Competition

Kura Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools